Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in
EZH2 inhibitor
chordoma
next-generation sequencing
patient-derived xenografts
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
13
02
2022
revised:
08
03
2022
accepted:
10
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Chordomas are rare neoplasms characterized by a high recurrence rate and a poor long-term prognosis. Considering their chemo-/radio-resistance, alternative treatment strategies are strongly required, but their development is limited by the paucity of relevant preclinical models. Mutations affecting genes of the SWI/SNF complexes are frequently found in chordomas, suggesting a potential therapeutic effect of epigenetic regulators in this pathology. Twelve PDX models were established and characterized on histological and biomolecular features. Patients whose tumors were able to grow into mice had a statistically significant lower progression-free survival than those whose tumors did not grow after in vivo transplantation (
Identifiants
pubmed: 35326637
pii: cancers14061486
doi: 10.3390/cancers14061486
pmc: PMC8946089
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Bone Joint Surg Am. 2010 May;92(5):1231-40
pubmed: 20439670
Neuro Oncol. 2014 Jan;16(1):72-80
pubmed: 24366975
Neurochirurgie. 2014 Jun;60(3):63-140
pubmed: 24856008
Neurosurgery. 2020 Feb 1;86(2):E118-E123
pubmed: 31504814
Lancet Oncol. 2018 May;19(5):649-659
pubmed: 29650362
PLoS One. 2013 Nov 15;8(11):e78895
pubmed: 24260133
J Orthop Res. 2012 Oct;30(10):1666-73
pubmed: 22504929
Cancer Metastasis Rev. 2016 Dec;35(4):547-573
pubmed: 28025748
Annu Rev Pathol. 2015;10:145-71
pubmed: 25387058
Eur Spine J. 2018 Dec;27(12):3043-3058
pubmed: 30220042
Sci Rep. 2017 Aug 23;7(1):9226
pubmed: 28835717
J Neuropathol Exp Neurol. 2020 Mar 1;79(3):314-324
pubmed: 31841164
Clin Cancer Res. 2019 Apr 1;25(7):2064-2071
pubmed: 30642912
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):350-66
pubmed: 25169151
Nat Commun. 2021 Feb 3;12(1):757
pubmed: 33536423
Genes Chromosomes Cancer. 2001 Nov;32(3):203-11
pubmed: 11579460
Int J Oncol. 2012 Feb;40(2):443-51
pubmed: 22002331
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
Oncotarget. 2015 Jun 30;6(18):16059-68
pubmed: 25965827
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
J Neurosurg Spine. 2014 Sep;21(3):386-93
pubmed: 24905390
Genes Dev. 2019 Aug 1;33(15-16):936-959
pubmed: 31123059
Sarcoma. 2010;2010:630129
pubmed: 21253487
J Neurosurg. 2014 Feb;120(2):331-6
pubmed: 24286145
Clin Cancer Res. 2007 Jul 1;13(13):3989-98
pubmed: 17606733
J Neurosurg. 2018 Mar;128(3):701-709
pubmed: 28430034
Acta Neuropathol. 1976 May 18;35(1):13-25
pubmed: 1274529
Acta Neuropathol. 2010 Dec;120(6):745-53
pubmed: 21057957
Nat Commun. 2017 Oct 12;8(1):890
pubmed: 29026114
J Pathol. 2021 Sep;255(1):72-83
pubmed: 34124783
Cell Cycle. 2020 Apr;19(7):758-771
pubmed: 32093567
World Neurosurg. 2014 Nov;82(5):806-14
pubmed: 25009165
J Neurosurg. 2012 Apr;116(4):801-9
pubmed: 22283186
Biochem Pharmacol. 2014 Jan 1;87(1):150-61
pubmed: 23817077
J Neurosurg. 2011 Oct;115(4):760-9
pubmed: 21699479
Am J Pathol. 2018 Dec;188(12):2902-2911
pubmed: 30248342
APMIS. 2019 Sep;127(9):607-615
pubmed: 31243811
J Neuropathol Exp Neurol. 2016 Feb;75(2):111-20
pubmed: 26733585
J Pathol. 2011 Feb;223(3):327-35
pubmed: 21171078
Nat Genet. 2013 Jun;45(6):592-601
pubmed: 23644491
Ann Oncol. 2017 Jun 1;28(6):1230-1242
pubmed: 28184416
BJU Int. 2014 May;113(5b):E157-63
pubmed: 24053427
Ann Diagn Pathol. 2013 Apr;17(2):192-7
pubmed: 23218904
PLoS One. 2013 Nov 06;8(11):e79950
pubmed: 24223206
Clin Cancer Res. 2010 Apr 15;16(8):2352-62
pubmed: 20371695
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752